Study summary
A B-cell antibody put six times as many people into complete remission as tacrolimus
37%in complete remission at 2 years, vs 6% with tacrolimus
What was tested
Obinutuzumab, an intravenous antibody that removes B cells (the source of the PLA2R antibodies behind most cases), against tacrolimus, an oral immunosuppressant, for primary membranous nephropathy.
What they found
- Complete remission at week 104: 37% with obinutuzumab vs 6% with tacrolimus.
- Complete or partial remission and complete remission at week 76 were also better.
- Serious side effects were similar (17% vs 14%); the eGFR endpoint was not significantly different.
What it means
Likely to make obinutuzumab a leading first treatment for membranous nephropathy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.